Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: testing DOAC for Ischemic Stroke

Atrial fibrillation (AF) is one of the most common cardiac arrhythmias and cardioembolic stroke due to AF is its major complication. Direct oral anticoagulants (DOAC) reduce the risk of cardioembolism in patients with AF.

Official registry: https://clinicaltrials.gov/study/NCT05976685 · Insel Gruppe AG, University Hospital Bern · enrollment listed as 482

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Left atrial appendage Occlusion, or DOAC. The registry lists allocation as randomized. Atrial fibrillation (AF) is one of the most common cardiac arrhythmias and cardioembolic stroke due to AF is its major complication.

They plan to enroll about 482 people at 34 sites. Taking part typically means taking a study drug (or dummy pill), a procedure as part of the study plus check-ins.

Official title (unrewritten)

Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic StrokE Despite Anticoagulation Therapy

Interventions: Left atrial appendage Occlusion, DOAC

Primary outcome (registry wording): Composite of recurrent ischemic stroke, systemic embolism, or cardiovascular death (whatever comes first).

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • Permanent, persistent, or paroxysmal spontaneous AF previously known or diagnosed during the index hospitalization
  • Recent (≤3 months) symptomatic ischemic stroke
  • Active or planned long-term therapy with DOAC

Public study contact (from the registry)

Lorenz Räber, Prof., MD, PhD

+41316320929

Lorenz.Raeber@insel.ch

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

34 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseSioux Falls, South Dakota
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute health information to support natural history studies, participant recruitment, and other research efforts.

NCT01793168 · Official ClinicalTrials.gov record · Sanford Health

RecruitingNot a traditional drug phaseCopenhagen
Not a traditional drug phase: CT angiography, FFR-CT and stress CT myocardial perfusion for Coronary Artery Disease

The purpose of the DYNAMITE trial (Dynamic CT stress myocardial perfusion, CT fractional flow reserve (FFR-CT) and coronary CT angiography for optimized treatment strategy in patients with chest pain syndromes) is to determine the ability of combined anatomical and functional cardiac CT imaging to improve morbidity and mortality in patients with suspected or known ischemic heart disease.

NCT04709900 · Official ClinicalTrials.gov record · Copenhagen University Hospital, Rigshospitalet

RecruitingNot a traditional drug phaseParis, Île-de-France Region
Not a traditional drug phase: Blood sampling for Cerebral Hypoxia

The goal of this trial is to study, in three well-defined clinical situations responsible for cerebral hypoxia, the concentrations of biomarkers of thrombo-inflammation compared to a population of patients without cerebral hypoxia, and to study in patients with cerebral hypoxia the association between these concentrations and the clinical evolution.

NCT04971564 · Official ClinicalTrials.gov record · Fondation Ophtalmologique Adolphe de Rothschild

FAQ about this NCT record

Is NCT05976685 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT05976685?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT05976685?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary